Table 1.
Patient demographic data
| Patient demographics | |||
|---|---|---|---|
| Characteristic | All N = 100 n(%) | Lung N = 78 n(%) | Head and neck N = 22 n(%) |
| Age (years) | |||
| Median (range) | 67 (30–80) | 68.5 (40–80) | 63.5 (30–74) |
| Gender | |||
| Male | 50 (50.0) | 36 (46.2) | 14 (63.6) |
| Female | 50 (50.0) | 42 (53.8) | 8 (36.4) |
| Stage | |||
| I | 3 (3.0) | 2 (2.6) | 1 (4.5) |
| II | 6 (6.0) | 2 (2.5) | 4 (18.2) |
| III | 38 (38.0) | 32 (41.1) | 6 (27.3) |
| IV | 41 (41.0) | 36 (46.2) | 5 (22.7) |
| Limited* | 2 (2.0) | 2 (2.6) | - |
| Extensive* | 2 (2.0) | 2 (2.5) | - |
| Unknown | 8 (8.0) | 2 (2.5) | 6 (27.3) |
| PS | |||
| 0 | 41 (41.0) | 26 (33.3) | 15 (68.2) |
| 1 | 45 (45.0) | 40 (51.3) | 5 (22.7) |
| 2 | 14 (14.0) | 12 (15.4) | 2 (9.1) |
| ACE comorbidity Score | |||
| 0 (None) | 37 (37.0) | 26 (33.3) | 11 (50.0) |
| 1 (Mild) | 39 (39.0) | 31 (39.7) | 8 (36.4) |
| 2 (Moderate) | 17 (17.0) | 16 (20.5) | 1 (4.5) |
| 3 (Severe) | 7 (7.0) | 5 (6.5) | 2 (9.1) |
Numbers in italics indicate percentage of total responses
Where ACE comorbidity scores were unavailable they were calculated by the researcher from the medical notes
ACE- Adult Comorbidity Evaluation, PS- Performance Status.* limited/extensive stage used for patients with small cell lung cancer